m6A modification-mediated lncRNA TP53TG1 inhibits gastric cancer progression by regulating CIP2A stability

Cancer Sci. 2022 Dec;113(12):4135-4150. doi: 10.1111/cas.15581. Epub 2022 Oct 7.

Abstract

Long noncoding RNAs (lncRNAs) are associated with various types of cancer. However, the precise roles of many lncRNAs in tumor progression remain unclear. In this study, we found that the expression of the lncRNA TP53TG1 was downregulated in gastric cancer (GC) and it functioned as a tumor suppressor. In addition, low TP53TG1 expression was significantly associated with poor survival in patients with GC. TP53TG1 inhibited the proliferation, metastasis, and cell cycle progression of GC cells, while it promoted their apoptosis. m6A modification sites are highly abundant on TP53TG1, and demethylase ALKBH5 reduces TP53TG1 stability and downregulates its expression. TP53TG1 interacts with cancerous inhibitor of protein phosphatase 2A (CIP2A) and triggers its ubiquitination-mediated degradation, resulting in the inhibition of the PI3K/AKT pathway. These results suggest that TP53TG1 plays an important role in inhibiting the progression of GC and provides a crucial target for GC treatment.

Keywords: ALKBH5; CIP2A; PI3K/AKT; TP53TG1; gastric cancer.

MeSH terms

  • Cell Line, Tumor
  • Cell Proliferation / genetics
  • Gene Expression Regulation, Neoplastic
  • Humans
  • Phosphatidylinositol 3-Kinases / metabolism
  • RNA, Long Noncoding* / genetics
  • RNA, Long Noncoding* / metabolism
  • Stomach Neoplasms* / pathology

Substances

  • Phosphatidylinositol 3-Kinases
  • RNA, Long Noncoding
  • CIP2A protein, human